Nasdaq
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The Software segment is focused on selling its software for drug discovery in the life sciences industry. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations.
Roles derived from SEC Form 4 filings.
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $108.1M | $137.9M | $181.0M | $216.7M | $207.5M | $255.9M |
| Gross profit | $63.5M | $65.6M | $101.0M | $140.7M | $132.1M | $142.6M |
| Operating income | -$60.9M | -$111.4M | -$146.8M | -$177.4M | -$209.3M | -$166.9M |
| Net income | -$24.5M | -$101.2M | -$149.2M | $40.7M | -$187.1M | -$103.3M |
| Diluted EPS | -$0.41 | -$1.42 | -$2.10 | $0.54 | -$2.57 | -$1.41 |
| Operating cash flow | $16.8M | -$70.7M | -$119.7M | -$136.7M | -$157.4M | $13.9M |
| Free cash flow | $14.2M | -$77.8M | -$127.7M | -$150.1M | -$164.7M | $12.5M |
| Gross margin | 58.7% | 47.6% | 55.8% | 64.9% | 63.6% | 55.7% |
| Operating margin | -56.4% | -80.8% | -81.1% | -81.9% | -100.8% | -65.2% |
| Net margin | -22.6% | -73.4% | -82.4% | 18.8% | -90.2% | -40.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $47.3M | $35.3M | $88.3M | $59.6M | $54.8M | $54.3M | $87.2M | $58.6M |
| Gross profit | $31.3M | $17.7M | $64.1M | $31.1M | $26.2M | $28.0M | $57.3M | $29.5M |
| Operating income | -$52.7M | -$68.4M | -$20.7M | -$50.9M | -$52.9M | -$45.9M | -$17.2M | -$48.8M |
| Net income | -$54.0M | -$38.1M | -$40.2M | -$59.8M | -$43.2M | -$32.8M | $32.5M | -$60.0M |
| Diluted EPS | -$0.74 | -$0.52 | -$0.55 | -$0.82 | -$0.59 | -$0.45 | $0.45 | -$0.81 |
| Operating cash flow | -$53.7M | -$33.3M | -$31.1M | $144.1M | -$52.2M | -$61.9M | -$16.1M | -$14.8M |
| Free cash flow | -$54.7M | -$34.6M | -$32.0M | $143.5M | -$52.5M | -$62.4M | -$16.1M | -$17.3M |
| Gross margin | 66.2% | 50.2% | 72.6% | 52.3% | 47.8% | 51.6% | 65.7% | 50.4% |
| Operating margin | -111.4% | -193.9% | -23.5% | -85.5% | -96.6% | -84.6% | -19.7% | -83.3% |
| Net margin | -114.2% | -108.1% | -45.5% | -100.4% | -78.8% | -60.4% | 37.3% | -102.5% |
Consensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-16 | Jain Rachit· EVP & CFO | Sale | 875 | $15.60 | $13,647.38 | filing |
| 2026-06-26 | Friesner Richard | Gift | 679,373 | $0.00 | $0.00 | filing |
| 2026-06-26 | Friesner Richard | Gift | 679,373 | $0.00 | $0.00 | filing |
| 2026-06-22 | OBEROI ARUN | Award | 8,141 | $0.00 | $0.00 | filing |
| 2026-06-22 | Chodakewitz Jeffrey | Award | 8,141 | $0.00 | $0.00 | filing |
| 2026-06-22 | Friesner Richard | Award | 8,141 | $0.00 | $0.00 | filing |
| 2026-06-22 | GINSBERG GARY L | Award | 8,141 | $0.00 | $0.00 | filing |
| 2026-06-22 | Kapeller-Libermann Rosana | Award | 8,141 | $0.00 | $0.00 | filing |
| 2026-06-22 | Lynton Michael | Award | 8,141 | $0.00 | $0.00 | filing |
| 2026-06-22 | Sender Gary | Award | 8,141 | $0.00 | $0.00 | filing |
| 2026-06-22 | Thornberry Nancy | Award | 8,141 | $0.00 | $0.00 | filing |
| 2026-06-22 | van Kralingen Bridget A | Award | 8,141 | $0.00 | $0.00 | filing |
| 2026-04-17 | Farid Ramy· President & CEO | Sale | 43,000 | $12.21 | $524,944.00 | filing |
| 2026-04-17 | Farid Ramy· President & CEO | Option exercise | 74,527 | $3.07 | $228,797.89 | filing |
| 2026-04-17 | Farid Ramy· President & CEO | Option exercise | 43,000 | $3.07 | $132,010.00 | filing |
| 2026-04-16 | Farid Ramy· President & CEO | Sale | 43,000 | $12.33 | $530,233.00 | filing |
| 2026-04-16 | Farid Ramy· President & CEO | Option exercise | 43,000 | $3.07 | $132,010.00 | filing |
| 2026-04-16 | Jain Rachit· EVP & CFO | Sale | 844 | $12.75 | $10,758.47 | filing |
| 2026-03-06 | Herman Jenny· CAO | Sale | 608 | $12.84 | $7,807.94 | filing |
| 2026-03-05 | Farid Ramy· President & CEO | Sale | 3,661 | $12.91 | $47,248.87 | filing |
| 2026-03-05 | Jain Rachit· EVP & CFO | Sale | 1,631 | $12.90 | $21,033.38 | filing |
| 2026-03-05 | Akinsanya Karen· See Remarks | Sale | 1,366 | $12.90 | $17,625.50 | filing |
| 2026-03-05 | Lorton Kenneth Patrick· EVP, CTO & COO, Software | Sale | 1,222 | $12.90 | $15,761.36 | filing |
| 2026-03-05 | Tran Yvonne· EVP, CLO & CPO | Sale | 1,094 | $12.90 | $14,107.13 | filing |
| 2026-03-05 | Herman Jenny· CAO | Sale | 775 | $12.85 | $9,955.65 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.